From Approval to Value: Evidence Storytelling, HEOR & Market Access
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
From Approval to Value: Evidence Storytelling, HEOR & Market Access
-
Narrated by:
-
By:
Summary
This episode is part two of a three-part series featured on Fierce Pharma’s The Top Line podcast.
Getting a therapy approved is only part of the journey, demonstrating its value is what drives access.
In this episode of Pharma Unscripted, we explore how evidence storytelling is becoming critical in biopharma. From real-world evidence (RWE) to health economics and outcomes research (HEOR), organizations must translate complex data into clear, decision-relevant insights.
As payers and HTA bodies demand stronger value demonstration, how you communicate evidence can directly impact patient access.
Key Topics:
- Evidence storytelling in biopharma
- HEOR and real-world evidence (RWE)
- Value communication for payers and HTAs
- Market access strategy
Guests:
- Kate Lothman, Director of Medical Writing & Publications
- Sara Musetti Jenkins, Principal Medical Writer
- Jason Crouch, Graphic Designer
adbl_web_anon_alc_button_suppression_c
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.